EP2116264A1 — Preparation for transnasal application
Assigned to Shin Nippon Biomedical Laboratories Ltd · Expires 2009-11-11 · 17y expired
What this patent protects
The present invention provides nasal preparations with improved flowability. The nasal preparations contain at least a complex of a physiologically active substance and a flowability-improving component containing: a first crystalline cellulose (A) having particular powder prope…
USPTO Abstract
The present invention provides nasal preparations with improved flowability. The nasal preparations contain at least a complex of a physiologically active substance and a flowability-improving component containing: a first crystalline cellulose (A) having particular powder properties; tribasic calcium phosphate (B) having particular powder properties; and a second crystalline cellulose (C) or starch (D) having particular powder properties.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.